Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. Ambardekar AV, Sarswat N, Wright R, Berk J, Davis MK, Garcia-Pavia P, Gillmore JD, Grodin JL, Mitchell JD, Mooney D, Nativi-Nicolau J, Poulsen SH, Ruberg FL, Chen C, Ji A, Siddhanti S, Tamby JF, Castaño A, Katz L, Sinha U, Fox JC, Maurer MS, Cheng RK. J Card Fail. 2026 May;32(5):864-876. doi: 10.1016/j.cardfail.2026.02.045. PMID: 42128580.
Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps. Chakraborty R, Brailovsky Y, Hanna M, Witteles R, Vaishnav J, Hoffman JE, Griffin J, Garcia-Pavia P, Wolinsky D, Karam C, Lachmann H, Gertz M, Boursiquot B, Bampatsias D, Hsu K, Johnson P, Zigterman J, Kazemzadeh AC, Maurer MS, Wechalekar A. Blood. 2026 May 21;147(21):2448-2462. doi: 10.1182/blood.2025031651. PMID: 41779722.
Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B. Sheikh FH, Dang J, Fontana M, Audard V, Garcia-Pavia P, Khouri MG, Jobbeé-Duval A, Brailovsky Y, Gillmore J, Zheng H, Eraly S, Moffitt C, Yilmaz A; HELIOS-B TRIAL INVESTIGATORS. J Card Fail. 2026 May;32(5):853-863. doi: 10.1016/j.cardfail.2026.02.049. PMID: 42128579.
Screening Strategies for Identification of Transthyretin Amyloid Cardiomyopathy. Peters AE, Ahmad FS, Martyn T, Grogan M, Hanna M, Maurer MS, Goyal P. JACC Heart Fail. 2026 May;14(5):103018. doi: 10.1016/j.jchf.2026.103018. Epub 2026 Mar 28. PMID: 41893375.
Rising Up to Meet our Patients on their Diagnostic and Treatment Odysseys. Gilotra NA, Maurer MS, Joyce E. J Card Fail. 2026 May;32(5):795-796. doi: 10.1016/j.cardfail.2026.04.009. PMID: 42128570.
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. Masri A, Cappelli F, Davis MK, Fontana M, Garcia-Pavia P, Gillmore JD, Hanna M, Obici L, Solomon SD, Sperry BW, Tahara N, Waddington-Cruz M, Kristen AV, Falk RH, Shah SJ, Nativi-Nicolau J, Viney NJ, Yang Q, Chen J, Tsimikas S, Maurer MS. Circ Heart Fail. 2026 May 9:e014205. doi: 10.1161/CIRCHEARTFAILURE.126.014205. Epub ahead of print. PMID: 42104840; PMCID: PMC13160239.
Disease Prognosis and Progression in Transthyretin Amyloidosis. Vaishnav J, Bampatsias D, Boursiquot BC, Brailovsky Y, Hsu K, Zigterman J, Chakraborty R, Wechalekar A, Pavia PG, Witteles R, Hanna M, Karam C, Maurer MS, Griffin JM. JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2026 Apr;8(2):120-136. doi: 10.1016/j.jaccao.2026.02.004. PMID: 42017563; PMCID: PMC13133650.
Cardiac amyloidosis: Disease overview and novel pathophysiologic insights. Tersalvi G, Tomasoni D, Coderre R, Kourelis TV, Dasgupta NR, Dispenzieri A, Flammer AJ, García-Pavía P, Gillmore JD, Grogan M, Hanna M, Maurer MS, Ruberg FL, AbouEzzeddine OF. J Nucl Cardiol. 2026 May;59S:102723. doi: 10.1016/j.nuclcard.2026.102723. Epub 2026 May 15. PMID: 42142944.
Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis. Fontana M, Algalarrondo V, Garcia-Pavia P, Maurer MS, Gillmore JD, Cappelli F, Kolachana K, Gao X, Jadhav S, Mehrotra N, Robbie G, Badri P. Clin Pharmacokinet. 2026 May 27. doi: 10.1007/s40262-026-01651-3. Epub ahead of print. PMID: 42201475.
Multidimensional Assessment of Disease Progression in a Contemporary Population With Transthyretin Amyloid Cardiomyopathy: Integrating Clinical Parameters, Biomarkers, Functionality, and Patient-Reported Outcomes. Bampatsias D, Levy J, Mirabal-Santos A, Cuomo M, Brailovsky Y, Wats K, Teruya S, Maurer MS. J Card Fail. 2026 May;32(5):811-820. doi: 10.1016/j.cardfail.2026.01.014. PMID: 42128573.
Fully Automated vs. Human Echocardiogram Interpretation in Transthyretin Amyloid Cardiomyopathy: The SCAN-MP Study. McMenamin KJ, Teruya S, Slivnick J, Alreshq R, Ullah I, Fine D, Elzieny AA, Helmke S, Gallegos C, Miller EJ, Asch FM, Hasan S, Maurer MS, Ruberg FL. J Am Soc Echocardiogr. 2026 Apr 29:S0894-7317(26)00176-8. doi: 10.1016/j.echo.2026.04.012. Epub ahead of print. PMID: 42066965; PMCID: PMC13182997.
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. Fontana M, Ambardekar AV, Cappelli F, Cuddy SAM, Davis MK, Garcia-Pavia P, Hanna M, Khouri MG, Masri A, Maurer MS, Obici L, Solomon S, Sperry BW, Tahara N, Waddington-Cruz M, Conrad T, Yang Q, Chen J, Tsimikas S, Gillmore JD. Eur J Heart Fail. 2026 May 30:xuag168. doi: 10.1093/ejhf/xuag168. Epub ahead of print. PMID: 42217207.
Stroke and Bleeding Risk in Cardiac Amyloidosis: A Danish Nationwide Matched Cohort Study. Noory N, Petersen JK, Westin O, Havers-Borgersen E, Køber L, Maurer MS, Rossing K, Gustafsson F, Fosbøl E. JACC Heart Fail. 2026 May 10:103147. doi: 10.1016/j.jchf.2026.103147. Epub ahead of print. PMID: 42153936.
Three-Dimensional Visualization and Proteomic Analysis of Human Cardiac Transthyretin Amyloidosis Tissue Reveals Microangiopathy and Capillary Occlusion. Donnelly JP, Schäfer JH, Yoon L, Massey LA, Ash C, Gao Z, Nugroho K, Jäger M, Pang Z, O'Neill RT, Maurer MS, Powers ET, Lander GC, Ye L, Kelly JW. J Am Heart Assoc. 2026 May 19;15(10):e042248. doi: 10.1161/JAHA.125.042248. Epub 2026 May 6. PMID: 42089154.
Poor R-wave progression associates with cerebral amyloid deposition: A potential link between heart and brain. Sozio SJ, Sahai A, Khalafi M, Wang X, Tanzi E, Harvey P, Maloney T, Hojjati SH, Zhou L, Pahlajani S, Butler TA, Glodzik L, Li Y, Razlighi Q, Kim J, Goyal P, Fossati S, Chiang GC. J Alzheimers Dis. 2026 Jun 4:13872877261449510. doi: 10.1177/13872877261449510. Epub ahead of print. PMID: 42244199.